1. Home
  2. CGON vs SFNC Comparison

CGON vs SFNC Comparison

Compare CGON & SFNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • SFNC
  • Stock Information
  • Founded
  • CGON 2010
  • SFNC 1903
  • Country
  • CGON United States
  • SFNC United States
  • Employees
  • CGON N/A
  • SFNC N/A
  • Industry
  • CGON
  • SFNC Major Banks
  • Sector
  • CGON
  • SFNC Finance
  • Exchange
  • CGON NYSE
  • SFNC Nasdaq
  • Market Cap
  • CGON 2.3B
  • SFNC 2.7B
  • IPO Year
  • CGON 2024
  • SFNC N/A
  • Fundamental
  • Price
  • CGON $29.08
  • SFNC $22.72
  • Analyst Decision
  • CGON Strong Buy
  • SFNC Hold
  • Analyst Count
  • CGON 10
  • SFNC 4
  • Target Price
  • CGON $65.11
  • SFNC $23.00
  • AVG Volume (30 Days)
  • CGON 809.2K
  • SFNC 701.5K
  • Earning Date
  • CGON 02-02-2025
  • SFNC 01-21-2025
  • Dividend Yield
  • CGON N/A
  • SFNC 3.70%
  • EPS Growth
  • CGON N/A
  • SFNC N/A
  • EPS
  • CGON N/A
  • SFNC 1.02
  • Revenue
  • CGON $684,000.00
  • SFNC $701,256,000.00
  • Revenue This Year
  • CGON $210.00
  • SFNC N/A
  • Revenue Next Year
  • CGON N/A
  • SFNC $8.98
  • P/E Ratio
  • CGON N/A
  • SFNC $22.31
  • Revenue Growth
  • CGON 258.12
  • SFNC N/A
  • 52 Week Low
  • CGON $25.77
  • SFNC $16.03
  • 52 Week High
  • CGON $50.23
  • SFNC $25.95
  • Technical
  • Relative Strength Index (RSI)
  • CGON 44.86
  • SFNC 52.69
  • Support Level
  • CGON $27.70
  • SFNC $22.13
  • Resistance Level
  • CGON $29.69
  • SFNC $22.89
  • Average True Range (ATR)
  • CGON 1.43
  • SFNC 0.60
  • MACD
  • CGON 0.16
  • SFNC 0.14
  • Stochastic Oscillator
  • CGON 31.29
  • SFNC 92.27

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About SFNC Simmons First National Corporation

Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers a range of products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. All the business activity of the firm is functioned through the region of the United States.

Share on Social Networks: